Rufinamide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Rufinamide
- Rufinamide: From Lennox-Gastaut Syndrome to Febrile Infection-Related Epilepsy Syndrome (FIRES)
Using the drug-repurposing evidence pack as the sole source, per top-ranked prediction (predicted_indications[0]).
Rufinamide: From Lennox-Gastaut Syndrome to Febrile Infection-Related Epilepsy Syndrome (FIRES)
One-Sentence Summary
Rufinamide is a triazole-derivative sodium-channel blocking anticonvulsant, historically used as adjunctive therapy for Lennox-Gastaut syndrome (LGS). The TxGNN model predicts it may be effective for Febrile Infection-Related Epilepsy Syndrome (FIRES), but currently no clinical trials and no literature in this evidence pack support this specific direction — the prediction is model-generated only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in this evidence pack (no EU marketing authorization on file); historically approved as adjunctive treatment for Lennox-Gastaut syndrome (LGS), per background literature cited elsewhere in this pack |
| Predicted New Indication | Febrile Infection-Related Epilepsy Syndrome (FIRES) |
| TxGNN Prediction Score | 99.57% |
| Evidence Level | L5 |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in structured form for this evidence pack (flagged as a High-severity data gap, DG002). Based on the literature retrieved elsewhere in this pack, rufinamide is understood to prolong the inactive state of voltage-gated Na⁺ channels, producing a membrane-stabilizing, broad-spectrum antiseizure effect. It is not chemically related to other marketed antiepileptics and is best known as an adjunctive therapy for Lennox-Gastaut syndrome (LGS), a severe childhood-onset developmental and epileptic encephalopathy.
FIRES is an extremely refractory epileptic encephalopathy that follows a febrile illness and is thought to be driven substantially by neuroinflammatory mechanisms rather than a classical channelopathy. The evidence pack’s own mechanistic rationale for this pairing is explicit that the link is theoretical: rufinamide’s Na⁺-channel mechanism is extrapolated by class analogy (broad-spectrum antiepileptic drug) rather than by any FIRES-specific pharmacology, and no clinical or preclinical data currently exist to confirm or refute it.
Because this is a pure knowledge-graph association with no corroborating trial or publication evidence, it should be treated as a research hypothesis only, not as a basis for clinical action.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (FIRES) is evidence level L5 (model prediction only, decision stage S0) — there is no clinical trial or literature evidence in this pack to support the drug-disease pairing, and the drug’s own regulatory/safety profile is undocumented here (0 EU authorizations on file).
To proceed, the following is needed:
- Resolve DG001 (Blocking): TFDA/SmPC warnings and contraindications must be sourced before any S1 safety screening can begin
- Resolve DG002 (High): Structured mechanism of action data from DrugBank, to validate or refute the Na⁺-channel rationale for FIRES
- Preclinical or case-level evidence specifically in FIRES (not general LGS/refractory-epilepsy data) before advancing past S0
- Confirmation of current EU marketing/licensing status, since this pack shows 0 active authorizations
Note for reviewers: This pack contains 10 ranked candidates for rufinamide. Rank 8, childhood onset epileptic encephalopathy, is functionally continuous with the drug’s already-established LGS indication and carries L1 evidence (systematic reviews, meta-analyses, and Phase III trial data) with a Proceed with Guardrails recommendation — it is a label-adjacent reconfirmation rather than a novel repurposing signal, but is worth separate evaluation if the goal includes indication-expansion documentation rather than genuinely new use cases.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.